Amgen (AMGN)
(Real Time Quote from BATS)
$325.40 USD
+3.49 (1.08%)
Updated Nov 8, 2024 03:42 PM ET
After-Market: $324.67 -0.73 (-0.22%) 4:06 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$325.40 USD
+3.49 (1.08%)
Updated Nov 8, 2024 03:42 PM ET
After-Market: $324.67 -0.73 (-0.22%) 4:06 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
Zacks News
Amgen (AMGN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed at $228.93 in the latest trading session, marking a +0.11% move from the prior day.
AbbVie's (ABBV) Q4 Earnings Surpass Estimates, Sales Miss
by Zacks Equity Research
AbbVie (ABBV) beats fourth-quarter 2021 earnings estimates while missing the same for sales. Strong demand for immunology drugs, aesthetics and cosmetics drives sales. Shares up.
Is a Beat Likely for Amgen (AMGN) This Earnings Season?
by Zacks Equity Research
Volume growth from Amgen's (AMGN) key drugs like Prolia, Kyprolis, Repatha and others and biosimilars portfolio is expected to have been partially offset by biosimilar/generic competition for mature drugs.
Eli Lilly (LLY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) fourth-quarter sales.
Will Merck (MRK) Succeed in Beating Q4 Earnings Expectations?
by Zacks Equity Research
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports Q4 earnings.
Bristol-Myers (BMY) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Bristol-Myers' (BMY) Q4 earnings might have gained from strong demand for its multiple myeloma drug, Revlimid. Operating expenses might have jumped on costs associated with the broader portfolio.
Is a Beat Likely for Biogen (BIIB) This Earnings Season?
by Zacks Equity Research
Investor focus is likely to be on sales of new Alzheimer's drug, Aduhelm when Biogen (BIIB) reports fourth-quarter results.
Will Eylea, Dupixent Aid Regeneron's (REGN) Q4 Earnings?
by Zacks Equity Research
Regeneron's (REGN) fourth-quarter performance might have gotten a boost from the solid performance of Eylea and Dupixent and incremental contribution from its antibody cocktail.
Gilead (GILD) to Report Q4 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Investors will focus on the HIV franchise's performance and Veklury sales in Gilead's (GILD) fourth-quarter 2021 results.
Can Value Investors Select Amgen (AMGN) Stock Now?
by Zacks Equity Research
Is Amgen (AMGN) a great pick from the value investor's perspective right now? Read on to know more.
Why Amgen (AMGN) Might Surprise This Earnings Season
by Zacks Equity Research
Amgen (AMGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Top Research Reports for Meta Platforms, UnitedHealth & salesforce
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Meta Platforms, Inc. (FB), UnitedHealth Group Incorporated (UNH), and salesforce.com, inc. (CRM).
Amgen (AMGN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Amgen (AMGN) closed at $224, marking a +0.66% move from the previous day.
Amgen (AMGN) to Report Q4 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amgen (AMGN) Stock Moves -0.52%: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed the most recent trading day at $227.72, moving -0.52% from the previous trading session.
Amgen's (AMGN) KRAS Inhibitor Gets Nod in Japan for Lung Cancer
by Zacks Equity Research
Amgen's (AMGN) KRAS inhibitor, Lumakras, gets approval in Japan for the treatment of KRAS G12C-mutated positive advanced/recurrent non-small-cell lung cancer.
J&J (JNJ) to Set the Stage for Pharma Sector Q4 Earnings
by Zacks Equity Research
J&J's (JNJ) Pharma segment is expected to have performed above the market. It remains to be seen if sales improved in the Medical Devices segment in the fourth quarter.
Amgen (AMGN) Stock Moves -1.04%: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed at $228.90 in the latest trading session, marking a -1.04% move from the prior day.
CytomX (CTMX) Gets FDA Nod to Begin Study in Solid Tumors
by Zacks Equity Research
The FDA clears CytomX's (CTMX) investigational new drug application for CX-904, which is being developed for the treatment of advanced solid tumors.
Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed at $235.36 in the latest trading session, marking a +1.95% move from the prior day.
BridgeBio (BBIO), Amgen Partner in Advanced Solid Tumors Study
by Zacks Equity Research
BridgeBio (BBIO) forges an alliance with Amgen to evaluate their respective cancer drugs for the treatment of advanced solid tumors with KRAS G12C mutations.
Stock Market News for Jan 13, 2022
by Zacks Equity Research
U.S. stocks closed slightly higher on Wednesday after data showed that inflation hit a four-decade high but came in largely in line with economists' expectations.
Biotech Stock Roundup: BIIB's AD Drug Update, AMGN's Drug Approval & Other Updates
by Zacks Equity Research
Regulatory and other pipeline updates from Biogen (BIIB) and AMGN are among a few key highlights from the biotech sector during the past week.
Why the Earnings Surprise Streak Could Continue for Amgen (AMGN)
by Zacks Equity Research
Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Amgen (AMGN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed at $230.37 in the latest trading session, marking a +1.36% move from the prior day.